JW Therapeutics (Shanghai) Co. Ltd.

Core Focus and Scientific Approach

The company's principal scientific focus is on engineered T-cell therapy, particularly CAR-T (chimeric antigen receptor T-cell) technology. This form of immunotherapy involves collecting a patient's own T-cells, genetically modifying them in a laboratory to express receptors that target specific cancer antigens, expanding these engineered cells, and then reinfusing them into the patient. Once reintroduced, the modified T-cells recognize and attack cancer cells bearing the targeted antigen.

JW Therapeutics leverages advanced cell engineering platforms, including technology relationships derived from its founding partnership with Juno Therapeutics. The company builds on validated CAR-T science while adapting it to the regulatory, clinical, and manufacturing landscape of China. Its work encompasses the full continuum of cell therapy development, from target identification and construct design through clinical trials, regulatory approval, commercial manufacturing, and patient delivery.

Products and Pipeline

Relmacabtagene Autoleucel (Carteyva / relma-cel)

The company's flagship and most significant product is relmacabtagene autoleucel, marketed under the brand name Carteyva (also referred to as relma-cel). This is a CD19-directed autologous CAR-T cell therapy. It holds particular importance as one of the first CAR-T products developed and approved in China under the country's Category 1 biologics regulatory pathway, representing a milestone in China's domestic cell therapy industry.

Carteyva is approved for the treatment of adult patients with relapsed or refractory large B-cell lymphoma (r/r LBCL) who have failed at least two lines of systemic therapy. The therapy targets the CD19 antigen, which is commonly expressed on the surface of malignant B-cells. The company has also pursued additional indications for this product, including relapsed or refractory follicular lymphoma and relapsed or refractory mantle cell lymphoma, broadening its use across multiple B-cell malignancies.

Broader Pipeline

Beyond its commercial product, JW Therapeutics maintains a development pipeline that explores additional CAR-T candidates and next-generation cell therapy approaches. The company has investigated therapies directed at other targets relevant to hematological cancers, including candidates aimed at multiple myeloma through targets such as BCMA (B-cell maturation antigen). It has also explored approaches intended to extend cell therapy into new indications and to improve upon the efficacy, safety, and accessibility of existing treatments.

The company's research and development efforts include work on technologies designed to enhance the durability and potency of engineered T-cells, as well as strategies aimed at addressing solid tumors and other diseases that have historically proven more challenging for cell therapy. In addition, JW Therapeutics has pursued allogeneic and universal cell therapy concepts, which aim to develop off-the-shelf products that do not require harvesting cells from each individual patient, potentially improving scalability and reducing treatment timelines.

Manufacturing and Operations

A defining strength of JW Therapeutics is its integrated cell therapy manufacturing capability. The production of autologous CAR-T therapies is highly complex, requiring stringent quality control, specialized facilities, and precise logistics to handle each patient's individualized cell product. The company operates commercial-scale manufacturing facilities in China that comply with Good Manufacturing Practice (GMP) standards, enabling it to produce cell therapy products consistently and reliably for clinical and commercial use.

The company has invested heavily in building an end-to-end supply chain that spans the collection of patient cells (apheresis), cryopreservation, transport, manufacturing, quality release, and delivery back to treatment centers. This closed-loop, patient-specific process demands close coordination between the company, hospitals, and treatment centers to ensure that each therapy reaches the correct patient within required timeframes.

Commercial and Clinical Network

JW Therapeutics has established relationships with treatment centers and qualified hospitals across China capable of administering CAR-T therapy. Because cell therapies require specialized clinical management, including monitoring for side effects such as cytokine release syndrome and neurotoxicity, the company works to certify and support hospital partners in delivering these treatments safely. The company also engages with Chinese regulatory authorities, including the National Medical Products Administration (NMPA), to advance its products through approval and to expand access.

Strategic Significance

JW Therapeutics occupies an influential position at the intersection of global cell therapy innovation and China's growing biopharmaceutical market. Its founding partnership brought together internationally validated CAR-T science and strong China-based operational capabilities, allowing it to bring advanced immunotherapies to Chinese patients who previously had limited access to such treatments. As one of the pioneers of commercial CAR-T therapy in China, the company plays a notable role in shaping the regulatory precedents, clinical practices, and manufacturing standards for cell therapy in the region.

Mission

The company's overarching mission centers on transforming the treatment of cancer and other life-threatening diseases by delivering safe, effective, and accessible cell-based immunotherapies. Through continued investment in research, manufacturing infrastructure, and clinical partnerships, JW Therapeutics aims to expand the reach of engineered cell therapies and to establish itself as a leading force in the global immunotherapy landscape, with a particular emphasis on serving patients in China and the broader Asia-Pacific region.